NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$1.4b

Last Updated

2021/09/19 22:05 UTC

Data Sources

Company Financials +

Executive Summary

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. More Details


Snowflake Analysis

Undervalued with adequate balance sheet.


Similar Companies

Share Price & News

How has Supernus Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SUPN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: SUPN's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

2.6%

SUPN

-2.5%

US Pharmaceuticals

-0.6%

US Market


1 Year Return

22.1%

SUPN

11.0%

US Pharmaceuticals

33.8%

US Market

Return vs Industry: SUPN exceeded the US Pharmaceuticals industry which returned 11% over the past year.

Return vs Market: SUPN underperformed the US Market which returned 33.8% over the past year.


Shareholder returns

SUPNIndustryMarket
7 Day2.6%-2.5%-0.6%
30 Day13.2%-8.5%1.0%
90 Day-16.7%-0.2%3.4%
1 Year22.1%22.1%15.6%11.0%35.8%33.8%
3 Year-44.2%-44.2%20.3%10.1%60.0%50.1%
5 Year4.2%4.2%49.9%30.5%123.0%98.7%

Long-Term Price Volatility Vs. Market

How volatile is Supernus Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Supernus Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

47.2%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SUPN ($27.28) is trading below our estimate of fair value ($51.68)

Significantly Below Fair Value: SUPN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SUPN is good value based on its PE Ratio (14.5x) compared to the US Pharmaceuticals industry average (22.9x).

PE vs Market: SUPN is good value based on its PE Ratio (14.5x) compared to the US market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: SUPN is poor value based on its PEG Ratio (1.2x)


Price to Book Ratio

PB vs Industry: SUPN is good value based on its PB Ratio (1.8x) compared to the US Pharmaceuticals industry average (3.2x).


Future Growth

How is Supernus Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

11.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SUPN's forecast earnings growth (11.6% per year) is above the savings rate (2%).

Earnings vs Market: SUPN's earnings (11.6% per year) are forecast to grow slower than the US market (14.8% per year).

High Growth Earnings: SUPN's earnings are forecast to grow, but not significantly.

Revenue vs Market: SUPN's revenue (1.8% per year) is forecast to grow slower than the US market (9.8% per year).

High Growth Revenue: SUPN's revenue (1.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SUPN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Supernus Pharmaceuticals performed over the past 5 years?

12.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SUPN has high quality earnings.

Growing Profit Margin: SUPN's current net profit margins (17.5%) are lower than last year (27.9%).


Past Earnings Growth Analysis

Earnings Trend: SUPN's earnings have grown by 12.1% per year over the past 5 years.

Accelerating Growth: SUPN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SUPN had negative earnings growth (-15.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (17.5%).


Return on Equity

High ROE: SUPN's Return on Equity (12.8%) is considered low.


Financial Health

How is Supernus Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: SUPN's short term assets ($639.2M) exceed its short term liabilities ($283.4M).

Long Term Liabilities: SUPN's short term assets ($639.2M) exceed its long term liabilities ($504.0M).


Debt to Equity History and Analysis

Debt Level: SUPN's debt to equity ratio (47.1%) is considered high.

Reducing Debt: SUPN's debt to equity ratio has increased from 5.1% to 47.1% over the past 5 years.

Debt Coverage: SUPN's debt is well covered by operating cash flow (32.4%).

Interest Coverage: SUPN's interest payments on its debt are well covered by EBIT (8.1x coverage).


Balance Sheet


Dividend

What is Supernus Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SUPN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SUPN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SUPN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SUPN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SUPN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.2yrs

Average management tenure


CEO

Jack Khattar (60 yo)

16.67yrs

Tenure

US$6,669,047

Compensation

Mr. Jack A. Khattar founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has served as its Chief Executive Officer, President, Secretary and Director since 2005. From 199...


CEO Compensation Analysis

Compensation vs Market: Jack's total compensation ($USD6.67M) is above average for companies of similar size in the US market ($USD3.69M).

Compensation vs Earnings: Jack's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: SUPN's management team is seasoned and experienced (6.2 years average tenure).


Board Members

Experienced Board: SUPN's board of directors are considered experienced (8.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Supernus Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Supernus Pharmaceuticals, Inc.
  • Ticker: SUPN
  • Exchange: NasdaqGM
  • Founded: 2005
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.450b
  • Shares outstanding: 53.15m
  • Website: https://www.supernus.com

Number of Employees


Location

  • Supernus Pharmaceuticals, Inc.
  • 9715 Key West Avenue
  • Rockville
  • Maryland
  • 20850
  • United States

Listings


Biography

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its comm...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/19 22:05
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.